Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodie... Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Show more
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.18 | -7.5 | 2.4 | 2.6 | 2.23 | 507730 | 2.45247467 | CS |
4 | -0.03 | -1.33333333333 | 2.25 | 2.6 | 2.06 | 332865 | 2.31596419 | CS |
12 | 0.15 | 7.24637681159 | 2.07 | 2.81 | 2 | 395877 | 2.36049082 | CS |
26 | 0.29 | 15.0259067358 | 1.93 | 2.81 | 1.38 | 380531 | 2.06843237 | CS |
52 | 0.59 | 36.1963190184 | 1.63 | 3.62 | 1.3 | 511396 | 2.11140693 | CS |
156 | -32.48 | -93.6023054755 | 34.7 | 46.4 | 1.3 | 538008 | 13.34218316 | CS |
260 | -21.38 | -90.593220339 | 23.6 | 53.762 | 1.3 | 634213 | 21.06853822 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.